SAB BIOTHERAPEUTICS INC (SABS) Stock Price, Forecast & Analysis
NASDAQ:SABS • US78397T2024
SABS Key Statistics, Chart & Performance
The current stock price of SABS is 3.74 USD. In the past month the price decreased by -9.44%. In the past year, price increased by 118.71%.
SABS Technical Analysis
ChartMill assigns a technical rating of 6 / 10 to SABS. When comparing the yearly performance of all stocks, SABS is one of the better performing stocks in the market, outperforming 92.63% of all stocks.
SABS Fundamental Analysis
ChartMill assigns a fundamental rating of 3 / 10 to SABS. The financial health of SABS is average, but there are quite some concerns on its profitability.
SABS Financial Highlights
Over the last trailing twelve months SABS reported a non-GAAP Earnings per Share(EPS) of -3.03. The EPS increased by 48.62% compared to the year before.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PM (TTM) | N/A | ||
| ROA | -11.65% | ||
| ROE | -12.94% | ||
| Debt/Equity | 0.02 |
SABS Forecast & Estimates
14 analysts have analysed SABS and the average price target is 9.56 USD. This implies a price increase of 155.68% is expected in the next year compared to the current price of 3.74.
For the next year, analysts expect an EPS growth of 87.71% and a revenue growth -100% for SABS
SABS Ownership
SABS Competitors/Peers
| Symbol | Company Name | Technical Rating | Fundamental Rating | FPE | Market Cap |
|---|---|---|---|---|---|
| ABBV | ABBVIE INC | 15.73 | 405.578B | ||
| AMGN | AMGEN INC | 16.99 | 204.31B | ||
| GILD | GILEAD SCIENCES INC | 16.55 | 185.891B | ||
| VRTX | VERTEX PHARMACEUTICALS INC | 23.91 | 122.042B | ||
| REGN | REGENERON PHARMACEUTICALS | 16.62 | 83.206B | ||
| ALNY | ALNYLAM PHARMACEUTICALS INC | 49.69 | 43.51B | ||
| INSM | INSMED INC | N/A | 33.916B | ||
| NTRA | NATERA INC | N/A | 29.129B | ||
| BIIB | BIOGEN INC | 12.83 | 28.815B | ||
| UTHR | UNITED THERAPEUTICS CORP | 16.06 | 20.433B |
Related stock screener links
View all stocks in the Biotechnology Industry | View all stocks in the Health Care Sector | View all stocks on the Nasdaq Exchange | Find stocks with similar TA and Setup ratings on the USA exchanges | Find stocks with similar Fundamental rating on the USA exchanges | Find the competitors with the best technical ratings on the USA exchanges | Find the competitors with the best fundamentals on the USA exchanges | Find the competitors with the best valuation on the USA exchanges | Find the competitors with the best dividend on the USA exchanges | Find the competitors with the best analyst ratings on the USA exchanges
About SABS
Company Profile
SAB Biotherapeutics, Inc. is a clinical-stage, biopharmaceutical company, which engages in advancing a new class of immunotherapies leveraging fully-human polyclonal antibodies. The company is headquartered in Miami Beach, Florida and currently employs 63 full-time employees. The company went IPO on 2021-01-12. The firm is focused on developing product candidates for disease targets where a differentiated approach has the greatest potential to be either first-in-class against novel targets or best-in-class against complex targets to treat diseases, including type 1 diabetes (T1D) and other autoimmune disorders. The Company’s lead product candidate, SAB-142, is a human anti-thymocyte globulin (ATG) focused on preventing or delaying the progression of T1D. SAB-142 is expected to reduce autoimmune beta cell destruction and delay progression or onset of T1D in patients with Stage III or Stage II T1D. The Company’s genetic engineering platform produces human, multi-targeted, high-potency immunoglobulins, without the need for human donors or convalescent plasma.
Company Info
SAB BIOTHERAPEUTICS INC
777 W 41St St, Suite 401
Miami Beach FLORIDA US
CEO: Samuel J. Reich
Employees: 63
Phone: 13058452813
SAB BIOTHERAPEUTICS INC / SABS FAQ
Can you describe the business of SAB BIOTHERAPEUTICS INC?
SAB Biotherapeutics, Inc. is a clinical-stage, biopharmaceutical company, which engages in advancing a new class of immunotherapies leveraging fully-human polyclonal antibodies. The company is headquartered in Miami Beach, Florida and currently employs 63 full-time employees. The company went IPO on 2021-01-12. The firm is focused on developing product candidates for disease targets where a differentiated approach has the greatest potential to be either first-in-class against novel targets or best-in-class against complex targets to treat diseases, including type 1 diabetes (T1D) and other autoimmune disorders. The Company’s lead product candidate, SAB-142, is a human anti-thymocyte globulin (ATG) focused on preventing or delaying the progression of T1D. SAB-142 is expected to reduce autoimmune beta cell destruction and delay progression or onset of T1D in patients with Stage III or Stage II T1D. The Company’s genetic engineering platform produces human, multi-targeted, high-potency immunoglobulins, without the need for human donors or convalescent plasma.
What is the current price of SABS stock?
The current stock price of SABS is 3.74 USD. The price increased by 1.91% in the last trading session.
Does SABS stock pay dividends?
SABS does not pay a dividend.
How is the ChartMill rating for SAB BIOTHERAPEUTICS INC?
SABS has a ChartMill Technical rating of 6 out of 10 and a ChartMill Fundamental rating of 3 out of 10.
Would investing in SAB BIOTHERAPEUTICS INC be a good decision?
This depends on your investment goals. Check the Technical and Fundamental Analysis tabs for insights on SABS.
Can you provide the growth outlook for SAB BIOTHERAPEUTICS INC?
The Revenue of SAB BIOTHERAPEUTICS INC (SABS) is expected to decline by -100% in the next year. Check the estimates tab for more information on the EPS, Sales, EBIT and EBITDA future analyst estimates.
Can you provide the ownership details for SABS stock?
You can find the ownership structure of SAB BIOTHERAPEUTICS INC (SABS) on the Ownership tab.